<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT: May 17, 1996
------------
ROTECH MEDICAL CORPORATION
--------------------------
(Exact name of Registrant as specified on its Charter)
Florida 59-2115892
- ----------------------------- ------------------
(State or jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
4506 L.B. McLeod Road, Suite F. Orlando, Florida 32811
- ------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (407) 841-2115
- ------------------------------------------------------------------------------
Not Applicable
- --------------
(former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events
- --------------------
FOR IMMEDIATE RELEASE
ROTECH MEDICAL CORPORATION ANNOUNCES
PROPOSED $100 MILLION CONVERTIBLE SUBORDINATED DEBENTURE
OFFERING
ORLANDO-(BUSINESS WIRE)--MAY 15, 1996--ROTECH MEDICAL CORPORATION
(NASDAQ/NMS-ROTC), today announced that it proposes to offer a new issue of $100
million of Convertible Subordinated Debentures due 2003 (the "Debentures").
The Debentures will be convertible into RoTech Common Stock, at the option of
the holder, at a price to be determined. The Company also may issue up to an
additional $15 million of Debentures to cover over-allotments in connection with
such offering. The Company intends to use the proceeds for the sale of the
Debentures to repay short term indebtedness.
The Debentures have not been registered under the Securities Act of 1933 and may
not be offered or sold in the United States, except pursuant to an applicable
exemption from the Securities Act of 1933 registration requirements. This
release shall not constitute an offer to sell or the solicitation of an offer to
buy the Debentures. This press release is being issued pursuant to and in
accordance with Rule 135c under the Securities Act of 1933.
<PAGE>
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
- --------------------------------------------------------------------------
(c) Exhibits
Press release entitled "For Immediate Release - RoTech Medical Corporation
Announces Proposed $100 million Convertible Subordinated Debenture Offering"
dated May 15, 1996.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report on 8-K to be signed on its behalf by the
undersigned hereunto duly authorized.
RoTech Medical Corporation,
a Florida Corporation
Dated: May 17 1996 By: /s/ Rebecca R. Irish
----------- ---------------------------
Rebecca R. Irish, Treasurer
and Chief Financial Officer
<PAGE>
Exhibit
[LOGO OF ROTECH MEDICAL CORPORATION]
4506 L.B. McLeod Road
Orlando, Florida 32811
407-841-2115
FAX 407-841-9318
Contact: Rebecca R. Irish
NEWS RELEASE
FOR IMMEDIATE RELEASE
ROTECH MEDICAL CORPORATION ANNOUNCES
PROPOSED $100 MILLION CONVERTIBLE SUBORDINATED
DEBENTURE OFFERING
ORLANDO--(BUSINESS WIRE)--May 15, 1996--ROTECH MEDICAL CORPORATION
(NASDAQ/NMS-ROTC), today announced that it proposes to offer a new issue of $100
million of Convertible Subordinated Debentures due 2003 (the "Debentures").
The Debentures will be convertible into RoTech Common Stock, at the option of
the holder, at a price to be determined. The Company also may issue up to an
additional $15 million of Debentures to cover over-allotments in connection with
such offering. The Company intends to use the proceeds for the sale of the
Debentures to repay short-term indebtedness.
The Debentures have not been registered under the Securities Act of 1933 and may
not be offered or sold in the United States, except pursuant to an applicable
exemption from the Securities Act of 1933 registration requirements. This press
release shall not constitute an offer to sell or the solicitation of an offer to
buy the Debentures. This press release is being issued pursuant to and in
accordance with Rule 135c under the Securities Act of 1933.
